HER-2/neu receptor in prostate cancer development and progression to androgen independence

Development of prostate cancer and progression to androgen-independent disease is correlated with increased expression of growth factors and receptors capable of establishing autocrine and/or paracrine growth-stimulatory loops. A thorough review was made of the current literature and recent abstract...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2004-03, Vol.90 (2), p.163-170
Main Authors: Di Lorenzo, Giuseppe, Autorino, Riccardo, De Laurentiis, Michele, Cindolo, Luca, D'Armiento, Massimo, Bianco, Angelo Raffaele, De Placido, Sabino
Format: Article
Language:English
Subjects:
Androgens - metabolism
Antineoplastic Agents - pharmacology
Biomarkers, Tumor - metabolism
Disease Progression
Gene Expression Regulation, Neoplastic - drug effects
Humans
Immunohistochemistry
Male
Neoplasms, Hormone-Dependent - metabolism
Prostate - metabolism
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - metabolism
Receptor Cross-Talk - drug effects
Receptor, Epidermal Growth Factor - drug effects
Receptor, Epidermal Growth Factor - metabolism
Receptor, ErbB-2 - drug effects
Receptor, ErbB-2 - metabolism
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of prostate cancer and progression to androgen-independent disease is correlated with increased expression of growth factors and receptors capable of establishing autocrine and/or paracrine growth-stimulatory loops. A thorough review was made of the current literature and recent abstract presentations at scientific meetings focusing on the role of the HER-2/neu (c-erbB2) receptor in prostate cancer and the potential clinical usefulness of its specific inhibitors. In the past 10 years, conflicting results on HER-2/neu expression in prostate cancer have been reported. More recently, four studies have shown experimental evidence of HER-2/neu in the development of prostate cancer and, more specifically, in the progression to a hormone-refractory clinical behavior. Furthermore, it has been proposed that HER-2 family and androgen receptors function synergistically in the absence of androgen, which suggests a cross-talk between the HER-2/neu and androgen receptor pathways. Finally, clinical trials are in progress in prostate cancer patients to test novel agents that selectively interfere with HER-2/neu activity.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089160409000201